Akari Therapeutics, Plc (AKTX)
After hours:
| Previous close | 1.1800 |
| Open | 1.2000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.2000 - 1.3512 |
| 52-week range | 1.0780 - 5.5000 |
| Volume | |
| Avg. volume | 12,091 |
| Market cap | 10.142M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief S
- GlobeNewswire
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challenging economic conditions during 2023 in the biotech sector and beyond, the Akari team advanced our Phase 3 and pre-clinical development programs and paved the way for a merger that, upon closi
- GlobeNewswire
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc,
